Your browser doesn't support javascript.
loading
Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14).
Echeverri, Jorge; Martins, Rui; Harenski, Kai; Kampf, J Patrick; McPherson, Paul; Textoris, Julien; Koyner, Jay L.
Afiliação
  • Echeverri J; Global Medical Affairs, Baxter Healthcare Corporation, Deerfield, IL, USA.
  • Martins R; University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Harenski K; Health Economics; Global Market Access Solutions, Saint Prex, Switzerland.
  • Kampf JP; Global Medical Affairs, Baxter Deutschland GmbH, Unterschleissheim, Germany.
  • McPherson P; Biomarker Research, Astute Medical Inc. (a bioMerieux Company), San Diego, CA, USA.
  • Textoris J; Biomarker Research, Astute Medical Inc. (a bioMerieux Company), San Diego, CA, USA.
  • Koyner JL; Medical Affairs; bioMerieux, SA, Lyon, France.
Clinicoecon Outcomes Res ; 16: 1-12, 2024.
Article em En | MEDLINE | ID: mdl-38235419
ABSTRACT

Background:

Approximately 24% of hospitalized stage 2-3 acute kidney injury (AKI) patients will develop persistent severe AKI (PS-AKI), defined as KDIGO stage 3 AKI lasting ≥3 days or with death in ≤3 days or stage 2 or 3 AKI with dialysis in ≤3 days, leading to worse outcomes and higher costs. There is currently no consensus on an intervention that effectively reverts the course of AKI and prevents PS-AKI in the population with stage 2-3 AKI. This study explores the cost-utility of biomarkers predicting PS-AKI, under the assumption that such intervention exists by comparing C-C motif chemokine ligand 14 (CCL14) to hospital standard of care (SOC) alone.

Methods:

The analysis combined a 90-day decision tree using CCL14 operating characteristics to predict PS-AKI and clinical outcomes in 66-year-old patients, and a Markov cohort estimating lifetime costs and quality-adjusted life years (QALYs). Cost and QALYs from admission, 30-day readmission, intensive care, dialysis, and death were compared. Clinical and cost inputs were informed by a large retrospective cohort of US hospitals in the PINC AI Healthcare Database. Inputs and assumptions were challenged in deterministic and probabilistic sensitivity analyses. Two-way analyses were used to explore the efficacy and costs of an intervention preventing PS-AKI.

Results:

Depending on selected costs and early intervention efficacy, CCL14-directed care led to lower costs and more QALYs (dominating) or was cost-effective at the $50,000/QALY threshold. Assuming the intervention would avoid 10% of PS-AKI complications in AKI stage 2-3 patients identified as true positive resulted in 0.066 additional QALYs and $486 reduced costs. Results were robust to substantial parameter variation.

Conclusion:

The analysis suggests that in the presence of an efficacious intervention preventing PS-AKI, identifying people at risk using CCL14 in addition to SOC is likely to represent a cost-effective use of resources.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clinicoecon Outcomes Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos